HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 286/4/F767    most recent 00337.2003v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Cui, T.-G. Articles by Harper, S. J. Search for Related Content PubMed PubMed Citation Articles by Cui, T.-G. Articles by Harper, S. J.

Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF₁₆₅b) mRNA and protein

¹Microvascular Research Laboratories, Department of Physiology, Preclinical Veterinary School, University of Bristol, Bristol BS2 8EJ; ³Childrens' and ⁴Academic Renal Unit, University of Bristol, and ⁵Bristol Urological Institute, Southmead Hospital, Bristol BS10 5NB, United Kingdom; and ²Institute of Nephrology, First Teaching Hospital, University of Beijing, Beijing 10034, Peoples' Republic of China

Submitted 22 September 2003 ; accepted in final form 21 November 2003

Despite production by podocytes of the proangiogenic molecule vascular endothelial growth factor-A (VEGF), the glomeruli are not sites of angiogenesis. We recently described mRNA expression of an inhibitory splice variant of VEGF (VEGF₁₆₅b) in normal kidney (Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D, and Harper SJ. Cancer Res 62: 4123–4131, 2002). Available anti-VEGF antibodies do not distinguish stimulatory from inhibitory VEGF families. To assess the production of VEGF₁₆₅ (stimulatory) and VEGF₁₆₅b (inhibitory) isoforms by human podocytes, we examined both primary cultured and conditionally immortalized human podocytes using family- and isoform-specific RT-PCR. In addition, VEGF protein production was analyzed in podocytes, using isoform-specific double-strand small-interference RNAs (siRNA). RT-PCR demonstrated the production of VEGF₁₈₉ mRNA by podocytes of both phenotypes. In contrast, on differentiation there was a splicing change from VEGF₁₆₅ to VEGF₁₆₅b mRNA. In addition, VEGF protein in the supernatant of conditionally immortalized, differentiated podocytes was reduced by VEGF₁₆₅b siRNA to 20 ± 11% of the level of mock-transfected cells (P < 0.01). No reduction was seen with mismatch siRNA. Moreover, there was no reduction in VEGF protein concentration in the supernatant of primary cultured, dedifferentiated human podocytes (109 ± 8% of mismatch siRNA, P > 0.1). In conclusion, differentiated but not dedifferentiated human podocytes secrete significant amounts of VEGF₁₆₅b protein. It is possible that this may explain the paradox of high VEGF production in the glomerulus but no angiogenesis. Furthermore, the existence of this splicing switch in relation to podocyte phenotype suggests that alternative splicing of the VEGF pre-RNA is a regulated process that is open to manipulation and therefore could be a target for novel cancer therapies.

angiogenesis; small-interference RNA; splicing

This article has been cited by other articles:

				S. N. Korgaonkar, X. Feng, M. D. Ross, T.-c. Lu, V. D'Agati, R. Iyengar, P. E. Klotman, and J. C. He HIV-1 Upregulates VEGF in Podocytes J. Am. Soc. Nephrol., May 1, 2008; 19(5): 877 - 883. [Abstract] [Full Text] [PDF]

				K. N. Lai, J. C. K. Leung, L. Y. Y. Chan, M. A. Saleem, P. W. Mathieson, F. M. Lai, and S. C. W. Tang Activation of podocytes by mesangial-derived TNF-{alpha}: glomerulo-podocytic communication in IgA nephropathy Am J Physiol Renal Physiol, April 1, 2008; 294(4): F945 - F955. [Abstract] [Full Text] [PDF]

				S. E. Quaggin and J. A. Kreidberg Development of the renal glomerulus: good neighbors and good fences Development, February 15, 2008; 135(4): 609 - 620. [Abstract] [Full Text] [PDF]

				J. Dai and A.B.M. Rabie VEGF: an Essential Mediator of Both Angiogenesis and Endochondral Ossification J. Dent. Res., October 1, 2007; 86(10): 937 - 950. [Abstract] [Full Text] [PDF]

				T. Ostendorf, A. S. De Vriese, and J. Floege Renal side effects of anti-VEGF therapy in man: a new test system Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2778 - 2780. [Full Text] [PDF]

				V. A. Schumacher, S. Jeruschke, F. Eitner, J. U. Becker, G. Pitschke, Y. Ince, J. H. Miner, I. Leuschner, R. Engers, A. S. Everding, et al. Impaired Glomerular Maturation and Lack of VEGF165b in Denys-Drash Syndrome J. Am. Soc. Nephrol., March 1, 2007; 18(3): 719 - 729. [Abstract] [Full Text] [PDF]

				F. Guan, G. Villegas, J. Teichman, P. Mundel, and A. Tufro Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP Am J Physiol Renal Physiol, August 1, 2006; 291(2): F422 - F428. [Abstract] [Full Text] [PDF]

				C. A. Glass, S. J. Harper, and D. O. Bates The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo J. Physiol., April 1, 2006; 572(1): 243 - 257. [Abstract] [Full Text] [PDF]

				K. Doi, E. Noiri, A. Nakao, T. Fujita, S. Kobayashi, and K. Tokunaga Functional Polymorphisms in the Vascular Endothelial Growth Factor Gene Are Associated with Development of End-Stage Renal Disease in Males J. Am. Soc. Nephrol., March 1, 2006; 17(3): 823 - 830. [Abstract] [Full Text] [PDF]

				P. W. Mathieson How Much VEGF Do You Need? J. Am. Soc. Nephrol., March 1, 2006; 17(3): 602 - 603. [Full Text] [PDF]

				C. D. Cohen, P. P. Doran, S. M. Blattner, M. Merkle, G. Q. Wang, H. Schmid, P. W. Mathieson, M. A. Saleem, A. Henger, M. P. Rastaldi, et al. Sam68-Like Mammalian Protein 2, Identified by Digital Differential Display as Expressed by Podocytes, Is Induced in Proteinuria and Involved in Splice Site Selection of Vascular Endothelial Growth Factor J. Am. Soc. Nephrol., July 1, 2005; 16(7): 1958 - 1965. [Abstract] [Full Text] [PDF]

				T. Gustafsson, H. Ameln, H. Fischer, C. J. Sundberg, J. A. Timmons, and E. Jansson VEGF-A splice variants and related receptor expression in human skeletal muscle following submaximal exercise J Appl Physiol, June 1, 2005; 98(6): 2137 - 2146. [Abstract] [Full Text] [PDF]

				R. R. Foster, M. A. Saleem, P. W. Mathieson, D. O. Bates, and S. J. Harper Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes Am J Physiol Renal Physiol, January 1, 2005; 288(1): F48 - F57. [Abstract] [Full Text] [PDF]

				J. Woolard, W.-Y. Wang, H. S. Bevan, Y. Qiu, L. Morbidelli, R. O. Pritchard-Jones, T.-G. Cui, M. Sugiono, E. Waine, R. Perrin, et al. VEGF165b, an Inhibitory Vascular Endothelial Growth Factor Splice Variant: Mechanism of Action, In vivo Effect On Angiogenesis and Endogenous Protein Expression Cancer Res., November 1, 2004; 64(21): 7822 - 7835. [Abstract] [Full Text] [PDF]

				S. Chen, Y. Kasama, J. S. Lee, B. Jim, M. Marin, and F. N. Ziyadeh Podocyte-Derived Vascular Endothelial Growth Factor Mediates the Stimulation of {alpha}3(IV) Collagen Production by Transforming Growth Factor-{beta}1 in Mouse Podocytes Diabetes, November 1, 2004; 53(11): 2939 - 2949. [Abstract] [Full Text] [PDF]